ERBB2 and breast carcinoma: In conclusion, the TH3RESA trial further confirmed the significant efficacy and favorable tolerability of T-DM1 in the treatment of HER2-positive advanced breast cancer, especially for patients who are refractory to other HER2-targeted therapies (Krop et al., 2014; Krop et al., 2017).